Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019

doi:10.1038/s41408-022-00656-y

. 2022 Apr 7;12(4):54.

doi: 10.1038/s41408-022-00656-y.

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019

Eiji Kusumi¹, Anju Murayama^{2

3}, Sae Kamamoto^{4

5}, Moe Kawashima^{4

6}, Makoto Yoshida⁴, Hiroaki Saito⁷, Toyoaki Sawano⁸, Erika Yamashita⁴, Tetsuya Tanimoto⁹, Akihiko Ozaki^{4

10}

Affiliations

¹ Department of Internal Medicine, Navitas Clinic Shinjuku, Shinjuku-ku, Tokyo, Japan.
² Medical Governance Research Institute, Minato-ku, Tokyo, Japan. ange21tera@gmail.com.
³ Tohoku University School of Medicine, Sendai City, Miyagi, Japan. ange21tera@gmail.com.
⁴ Medical Governance Research Institute, Minato-ku, Tokyo, Japan.
⁵ Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
⁶ Fukushima Medical University, Fukushima City, Fukushima, Japan.
⁷ Department of Gastroenterology, Sendai Kosei Hospital, Sendai City, Miyagi, Japan.
⁸ Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki City, Fukushima, Japan.
⁹ Department of Internal Medicine, Navitas Clinic, Tachikawa City, Tokyo, Japan.
¹⁰ Department of Breast and Thyroid Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki City, Fukushima, Japan.

PMID: 35393417
PMCID: PMC8989935
DOI: 10.1038/s41408-022-00656-y

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019

Eiji Kusumi et al. Blood Cancer J. 2022.

. 2022 Apr 7;12(4):54.

doi: 10.1038/s41408-022-00656-y.

Authors

Eiji Kusumi¹, Anju Murayama^{2

3}, Sae Kamamoto^{4

5}, Moe Kawashima^{4

6}, Makoto Yoshida⁴, Hiroaki Saito⁷, Toyoaki Sawano⁸, Erika Yamashita⁴, Tetsuya Tanimoto⁹, Akihiko Ozaki^{4

10}

Affiliations

¹ Department of Internal Medicine, Navitas Clinic Shinjuku, Shinjuku-ku, Tokyo, Japan.
² Medical Governance Research Institute, Minato-ku, Tokyo, Japan. ange21tera@gmail.com.
³ Tohoku University School of Medicine, Sendai City, Miyagi, Japan. ange21tera@gmail.com.
⁴ Medical Governance Research Institute, Minato-ku, Tokyo, Japan.
⁵ Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
⁶ Fukushima Medical University, Fukushima City, Fukushima, Japan.
⁷ Department of Gastroenterology, Sendai Kosei Hospital, Sendai City, Miyagi, Japan.
⁸ Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki City, Fukushima, Japan.
⁹ Department of Internal Medicine, Navitas Clinic, Tachikawa City, Tokyo, Japan.
¹⁰ Department of Breast and Thyroid Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki City, Fukushima, Japan.

PMID: 35393417
PMCID: PMC8989935
DOI: 10.1038/s41408-022-00656-y

No abstract available

PubMed Disclaimer

Conflict of interest statement

For the financial competing interests, EK received personal fees from Otsuka Pharmaceutical Co., Ltd outside the scope of the submitted work. HS received personal fees from Taiho Pharmaceutical Co. Ltd outside the scope of the submitted work. AO and TT received personal fees from Medical Network Systems outside the scope of the submitted work. TT also received personal fees from Bionics Co. Ltd, outside the scope of the submitted work. Regarding non-financial competing interests among the study authors, all are engaged in ongoing research examining financial and non-financial competing interests among healthcare professionals and pharmaceutical companies in Japan. Individually, AM, SK, HS, TS, TT, and AO have contributed to several published studies assessing competing interests and quality of evidence among clinical practice guideline authors in Japan and the United States. Among their previous articles, the authors have self-cited several articles in this study to gain deeper insights and explain the context of financial competing interests among healthcare professionals in Japan. EK was a hematology specialist board-certified by the Japanese Society of Hematology. The other authors have no example competing interests to disclose.

Cited by

Increasing trends of pharmaceutical payments to breast cancer specialists in Japan: A retrospective study from 2016 to 2019.
Kaneda Y, Yamashita E, Saito H, Gonda K, Wada M, Tanimoto T, Ozaki A. Kaneda Y, et al. PLoS One. 2024 Sep 26;19(9):e0310880. doi: 10.1371/journal.pone.0310880. eCollection 2024. PLoS One. 2024. PMID: 39325782 Free PMC article.
Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019.
Murayama A, Kamamoto S, Saito H, Yamada K, Bhandari D, Shoji I, Mamada H, Kawashima M, Yamashita E, Kusumi E, Sawano T, Sapkota B, Tanimoto T, Ozaki A. Murayama A, et al. Int J Environ Res Public Health. 2022 Jun 16;19(12):7417. doi: 10.3390/ijerph19127417. Int J Environ Res Public Health. 2022. PMID: 35742661 Free PMC article.
Assessment of Financial Relationships Between Otorhinolaryngologists and Pharmaceutical Companies in Japan Between 2016 and 2019.
Kamamoto S, Ozaki A, Murayama A. Kamamoto S, et al. Cureus. 2023 Aug 17;15(8):e43633. doi: 10.7759/cureus.43633. eCollection 2023 Aug. Cureus. 2023. PMID: 37719565 Free PMC article.
The Trend in Industry Payments During the COVID-19 Pandemic Among Gastroenterologists and Hepatologists in the United States.
Murayama A, Kamamoto S, Saito H, Tanimoto T, Ozaki A. Murayama A, et al. Cureus. 2022 Dec 19;14(12):e32711. doi: 10.7759/cureus.32711. eCollection 2022 Dec. Cureus. 2022. PMID: 36686074 Free PMC article.
Pharmaceutical Payments to Japanese Board-Certified Head and Neck Surgeons Between 2016 and 2019.
Murayama A, Shigeta H, Kamamoto S, Yamashita E, Saito H, Sawano T, Bhandari D, Shrestha S, Kusumi E, Tanimoto T, Ozaki A. Murayama A, et al. OTO Open. 2023 Feb 17;7(1):e31. doi: 10.1002/oto2.31. eCollection 2023 Jan-Mar. OTO Open. 2023. PMID: 36998569 Free PMC article.

See all "Cited by" articles

References

1. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020;323:844–53. doi: 10.1001/jama.2020.1166. - DOI - PMC - PubMed
1. Mitchell AP, Trivedi NU, Gennarelli RL, Chimonas S, Tabatabai SM, Goldberg J, et al. Are financial payments from the pharmaceutical industry associated with physician prescribing? A systematic review. Ann Intern Med. 2020;174:353–361. doi: 10.7326/M20-5665. - DOI - PMC - PubMed
1. Japan Pharmaceutical Manufacturers Association. Data Book 2021 Online. 2021. https://www.jpma.or.jp/news_room/issue/databook/2021_en/lofurc0000004we3....
1. Inoue K, Blumenthal DM, Elashoff D, Tsugawa Y. Association between physician characteristics and payments from industry in 2015–2017: observational study. BMJ Open. 2019;9:e031010. doi: 10.1136/bmjopen-2019-031010. - DOI - PMC - PubMed
1. Marshall DC, Moy B, Jackson ME, Mackey TK, Hattangadi-Gluth JA. Distribution and patterns of industry-related payments to oncologists in 2014. JNCI. 2016;108:djw163.. doi: 10.1093/jnci/djw163. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources

[1] Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020;323:844–53. doi: 10.1001/jama.2020.1166. - DOI - PMC - PubMed

[2] Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020;323:844–53. doi: 10.1001/jama.2020.1166. - DOI - PMC - PubMed

[3] Mitchell AP, Trivedi NU, Gennarelli RL, Chimonas S, Tabatabai SM, Goldberg J, et al. Are financial payments from the pharmaceutical industry associated with physician prescribing? A systematic review. Ann Intern Med. 2020;174:353–361. doi: 10.7326/M20-5665. - DOI - PMC - PubMed

[4] Mitchell AP, Trivedi NU, Gennarelli RL, Chimonas S, Tabatabai SM, Goldberg J, et al. Are financial payments from the pharmaceutical industry associated with physician prescribing? A systematic review. Ann Intern Med. 2020;174:353–361. doi: 10.7326/M20-5665. - DOI - PMC - PubMed

[5] Japan Pharmaceutical Manufacturers Association. Data Book 2021 Online. 2021. https://www.jpma.or.jp/news_room/issue/databook/2021_en/lofurc0000004we3....

[6] Japan Pharmaceutical Manufacturers Association. Data Book 2021 Online. 2021. https://www.jpma.or.jp/news_room/issue/databook/2021_en/lofurc0000004we3....

[7] Inoue K, Blumenthal DM, Elashoff D, Tsugawa Y. Association between physician characteristics and payments from industry in 2015–2017: observational study. BMJ Open. 2019;9:e031010. doi: 10.1136/bmjopen-2019-031010. - DOI - PMC - PubMed

[8] Inoue K, Blumenthal DM, Elashoff D, Tsugawa Y. Association between physician characteristics and payments from industry in 2015–2017: observational study. BMJ Open. 2019;9:e031010. doi: 10.1136/bmjopen-2019-031010. - DOI - PMC - PubMed

[9] Marshall DC, Moy B, Jackson ME, Mackey TK, Hattangadi-Gluth JA. Distribution and patterns of industry-related payments to oncologists in 2014. JNCI. 2016;108:djw163.. doi: 10.1093/jnci/djw163. - DOI - PMC - PubMed

[10] Marshall DC, Moy B, Jackson ME, Mackey TK, Hattangadi-Gluth JA. Distribution and patterns of industry-related payments to oncologists in 2014. JNCI. 2016;108:djw163.. doi: 10.1093/jnci/djw163. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019

Affiliations

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources